GlassScriptPhysician profile
David Benjamin Schuchman
NPI 1336231273
$1,933.31
in general payments reported to CMS, 2019-2025
19 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $32.46 · 2021: $218 · 2022: $316 · 2023: $496 · 2024: $402 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $360.93 | 2021-2025 | |
| Amgen INC. | $360.50 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $353.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.60 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $126.21 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.50 | 2021-2023 | Jardiance |
| Cvrx, INC. | $43.96 | 2023 | Barostim Neo System |
| Bridgebio Pharma, INC. | $40.38 | 2025 | Attruby |
| Shockwave Medical, INC | $39.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.30 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $29.20 | 2021-2023 | |
| Boston Scientific Corporation | $27.46 | 2021-2024 | Watchman Access System |
| Medtronic, INC. | $20.83 | 2021 | |
| Esperion Therapeutics, INC. | $18.68 | 2021 | |
| United Therapeutics Corporation | $18.55 | 2024 | Tyvaso |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.99 | 2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $15.34 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schuchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.